Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines

Table 2 Significant upregulated genes in resistant cell lines

HCT116 CM-R vs HCT116			LOVO CM-R vs LOVO
Gene Name	Gene Symbol	Fold change	Gene Name	Gene Symbol	Fold change
Neurofibromin 1	NF1	7,860,121	Insulin-like growth factor binding protein 7	IGFBP7	786,601
Erb-b2 receptor tyrosine kinase 3	ERBB3	6,631,199	Insulin receptor substrate 2	IRS2	7,395,454
Epidermal growth factor receptor	EGFR	5,149,977	Amphiregulin	AREG	4,963,224
E-cadherin	CDH1	3,811,482	Epidermal growth factor receptor	EGFR	455,673
Erbb2 interacting protein	ERBB2IP	3,587,709	Epiregulin	EREG	4,104,191
Insulin induced gene 2	INSIG2	3,514,022	Insulin induced gene 1	INSIG1	3,779,914
Insulin induced gene 1	INSIG1	2,569,083	Insulin induced gene 2	INSIG2	3,444,767
Erb-b2 receptor tyrosine kinase 2	ERBB2	2,387,238	Vimentin	VIM	290,101
Mitogen-activated protein kinase kinase kinase 10	MAP3K10	2,319,185	E-cadherin	CDH1	2,866,793
V-akt murine thymoma viral oncogene homolog 2	AKT2	2,270,916	V-akt murine thymoma viral oncogene homolog 3	AKT3	2,849,459
Transforming growth factor alpha	TGFA	2,015,933	Transforming growth factor alpha	TGFA	2,341,766
Insulin receptor substrate 2	IRS2	2,009,206	ERBB receptor feedback inhibitor 1	ERRFI1	2,141,185

Microarray analysis on HCT116 and LOVO resistant vs parental cell lines show recurrent upregulations of genes involved in HER, Insulin and AKT signaling

ISSN: 1756-9966